Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A clinical deep-dive into resmetirom dosing, pharmacogenomics, and efficacy data for Black and African ancestry patients with NASH/MASH, including ethnicity-stratified MAESTRO-NASH subgroup analysis and CYP2C8/OATP1B1/G6PD pharmacogenomic considerations.
Read clinical reviewA clinical review of resmetirom (Rezdiffra) efficacy and pharmacogenomic differences in East Asian patients, covering MAESTRO-NASH subgroup data, CYP2C19/CYP2D6 allele frequencies, BMI thresholds, and dosing considerations.
Read clinical reviewA clinician-focused guide to resmetirom dosing in Hispanic and Latino patients, covering MAESTRO-NASH subgroup data, CYP2C8 pharmacogenomics, NASH disease burden, and when a 60 mg vs. 100 mg starting dose is appropriate.
Read clinical reviewA detailed clinical review of resmetirom (Rezdiffra) efficacy data stratified by Black / African ancestry, including MAESTRO-NASH subgroup analysis, pharmacogenomic considerations, and dosing guidance for this population.
Read clinical reviewEvidence-based review of resmetirom (Rezdiffra) efficacy in Hispanic and Latino populations, including MAESTRO-NASH subgroup data, CYP enzyme variants, and clinical dosing considerations for MASH treatment.
Read clinical reviewEvidence review of resmetirom (Rezdiffra) efficacy in South Asian populations, covering MAESTRO-NASH subgroup data, pharmacogenomic variability, THR-β agonism, MASH prevalence disparities, and adjusted dosing considerations.
Read clinical reviewA clinician-focused review of resmetirom pharmacogenomics, dosing considerations, and safety signals in South Asian patients with NASH/MASH, including ethnicity-stratified data from MAESTRO-NASH and population pharmacokinetic evidence.
Read clinical review